doi: 10.1371/journal.pmed.0040292.
Randomized trials to optimize treatment of multidrug-resistant tuberculosis
Affiliations
- PMID: 17988168
- PMCID: PMC2062482
- DOI: 10.1371/journal.pmed.0040292
Item in Clipboard
Randomized trials to optimize treatment of multidrug-resistant tuberculosis
PLoS Med.
.
Abstract
The time is now right for randomized trials of MDR-TB, say the authors, as the expansion of MDR-TB programs provides the setting in which trials can be implemented.
Conflict of interest statement
Similar articles
-
State of the Art series on drug-resistant tuberculosis: it's time to protect fluoroquinolones.Int J Tuberc Lung Dis. 2009 Nov;13(11):1319. Int J Tuberc Lung Dis. 2009. PMID: 19861001 No abstract available.
-
What is new in the WHO consolidated guidelines on drug-resistant tuberculosis treatment?Indian J Med Res. 2019 Mar;149(3):309-312. doi: 10.4103/ijmr.IJMR_579_19. Indian J Med Res. 2019. PMID: 31249191 Free PMC article. No abstract available.
-
Tuberculosis; opportunities for treatment optimization.Curr Pharm Des. 2011;17(27):2852. doi: 10.2174/138161211797470219. Curr Pharm Des. 2011. PMID: 21834758 No abstract available.
-
Mechanisms of drug resistance in Mycobacterium tuberculosis.Int J Tuberc Lung Dis. 2009 Nov;13(11):1320-30. Int J Tuberc Lung Dis. 2009. PMID: 19861002 Review.
-
Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?Korean J Intern Med. 2016 Jan;31(1):15-29. doi: 10.3904/kjim.2016.31.1.15. Epub 2015 Dec 28. Korean J Intern Med. 2016. PMID: 26767853 Free PMC article. Review.
Cited by
-
European union standards for tuberculosis care.Eur Respir J. 2012 Apr;39(4):807-19. doi: 10.1183/09031936.00203811. Eur Respir J. 2012. PMID: 22467723 Free PMC article.
-
Extensively drug-resistant tuberculosis: a new face to an old pathogen.Annu Rev Med. 2009;60:307-20. doi: 10.1146/annurev.med.60.053107.103955. Annu Rev Med. 2009. PMID: 19630575 Free PMC article. Review.
-
Unorthodox approach to the development of a new antituberculosis therapy.N Engl J Med. 2009 Jun 4;360(23):2466-7. doi: 10.1056/NEJMe0903012. N Engl J Med. 2009. PMID: 19494223 Free PMC article. No abstract available.
-
TMC207: the first compound of a new class of potent anti-tuberculosis drugs.Future Microbiol. 2010 Jun;5(6):849-58. doi: 10.2217/fmb.10.50. Future Microbiol. 2010. PMID: 20521931 Free PMC article. Review.
-
Ethics, human rights and programmatic management of drug-resistant tuberculosis.Lung India. 2012 Jan;29(1):95-6. doi: 10.4103/0970-2113.92384. Lung India. 2012. PMID: 22345934 Free PMC article. No abstract available.
References
-
- Aziz MA, Wright A, Laszlo A, De Muynck A, Portaels F, et al. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): An updated analysis. Lancet. 2006;368:2142–2154. - PubMed
-
- Manissero D, Fernandez de la Hoz K. Surveillance methods and case definition for extensively drug resistant TB (XDR-TB) and relevance to Europe: Summary update. Euro Surveill. 2006;11:E061103.1. - PubMed
-
- Centers for Disease Control and Prevention (CDC) Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs—Worldwide, 2000–2004. MMWR Morb Mortal Wkly Rep. 2006;55:301–305. - PubMed
-
- Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:1575–1580. - PubMed
-
- Masjedi MR, Farnia P, Sorooch S, Pooramiri MV, Mansoori SD, et al. Extensively drug-resistant tuberculosis: 2 years of surveillance in Iran. Clin Infect Dis. 2006;43:841–847. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
